Save The Date: November 1-2, 2017
10 on the Park, New York City

Speakers

2016 Speakers and Participants

  • Wade Ackerman, Partner, Covington & Burling LLP
  • Karen Akinsanya, PhD, Associate Vice President, Head, Early Stage Scientific Assessment, Merck
  • Franklin M. Berger, CFA, Managing Director, FMB Research
  • Laurence Blumberg, MD, Founder & Chief Operating Officer, Syntimmune, Inc.
  • Jeffrey M. Bockman, PhD, Vice President, Defined Health
  • Jarrod Borkat, MBA, Senior Director, Head of External Collaborations and Government Contracts, MedImmune LLC
  • Keith A. Bostian, PhD, Chief Executive Officer, Institute for Life Science Entrepreneurship (ILSE)
  • Scott P. Bruder, MD, PhD, Bruder Consulting International, LLC
  • Chris Cain, PhD, Associate, Appletree Partners
  • Stephen Chang, PhD, Senior Vice President for Strategic Initiatives, The New York Stem Cell Foundation
  • Hina W. Chaudhry, MD, Associate Professor of Medicine, Director, Cardiovascular Regenerative Medicine, Mount Sinai School of Medicine
  • Ellen B. Corenswet, Partner, Covington & Burling LLP
  • Kate de Santis, Vice President of Investor Relations Iroko Pharmaceuticals, LLC
  • Christopher de Souza, PhD, MBA, Director, Broadview Ventures, Inc.
  • Eleanor “Ellie” Dehoney, Vice President, Policy and Advocacy, Research!America
  • Peter DeLuca, MS, Partner, Carter, DeLuca, Farrell & Schmidt, LLP
  • Kenneth Emancipator, MD, Executive Medical Director and Head, Companion Diagnostics, Merck Research Laboratories
  • Rebecca Farkas, PhD, Associate Director for Strategic Collaborations, MedImmune
  • David Filer, PhD,Advisor, SternAegis Ventures
  • Christine Fischette, PhD, Advisor, Torreya Partners
  • Stephanie Fertig, MBA, Director, NINDS Small Business Programs, National Institute of Neurological Disorders and Stroke, National Institutes of Health
  • Thomas Gallagher, Principal, Fenagh Group
  • Kaushik Ghosal, PhD, Director of Business Development, BioMotiv
  • Edwin H. Gordon, MBA, Co-Head of Healthcare Investment Banking, Ladenburg Thalmann
  • Sherry Grisewood, CFA, Managing Partner, Life Science Research, Dawson James Securities
  • Joseph V. Gulfo, MD, MBA, Executive Director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University
  • Dario A. Gutierrez, PhD, Immuno-biology Lead, Merck Research Labs- Cambridge Exploratory Science Center
  • Kimberly Ha, Senior Director, FTI Consulting
  • Todd Haim, PhD, Program Director, SBIR Development Center, National Cancer Institute, National Institutes of Health
  • Dov Hass, Director, Transactions and Corporate Law, Regeneron Pharmaceuticals
  • Kenton C. Hasson, PhD, Senior Manager, Business Development & Innovation, Canon BioMedical
  • William G Hearl, PhD, Chief Executive Officer, Immunomic Therapeutics, Inc.
  • Cláudia Hirawat, Independent BD Consultant & Advisor
  • Paul Howard, Senior Fellow, Director, Health Policy, Manhattan Institute
  • Nouhad Husseini, MBA, Senior Director, Business Development, Regeneron Pharmaceuticals
  • Stefan Irion, MD, Program Manager, New York State Stem Cell Science Consortia, Memorial Sloan Kettering Cancer Center
  • Stuart Jacobowitz, Director of Business Development, FreeMind Group
  • Anna Kazanchyan, MD, Founder & CEO, Saghmos Therapeutics Inc.
  • Pavel Khrimian, Associate Director, External Collaborations and Diagnostics Business Development, MedImmune LLC
  • Kevin Koch, PhD, Venture Partner, Orbimed
  • Kristen Kosofsky, Senior Managing Director, Hercules Technology Capital
  • Steven Kreit, Partner, EisnerAmper
  • Joan Kutcher, Of Counsel, Covington & Burling, LLP
  • Jennifer LaVin, MBA, Principal SMP Communications
  • Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer, Caladrius Biosciences
  • Ellen Lubman, MBA, Vice President, External Science & Innovation, Allergan PLC
  • Sanford J. Madigan, PhD, Senior Vice President, COI Pharmaceuticals, Inc.
  • Michael Marino, PhD, Manager, GE Global Research
  • Stephen Nagler, Executive Director, MedPro Investors LLC
  • Marian T. Nakada, PhD, Vice President Venture Investments, Johnson & Johnson Innovation – JJDC Inc. 
  • Ron Newbold, MS, MBA, PhD, Vice President, External R&D Innovation – Head Global Scouting, Pfizer
  • Bernat Olle, PhD, Co-Founder, Chief Executive Officer, Vedanta Biosciences
  • Brian P. O’Shaughnessy, Shareholder, RatnerPrestia; President-elect of Licensing Executives Society (LES). (USA & Canada)
  • Art Pappas, MBA, Managing Partner, Pappas Ventures
  • Ronit Phail, PhD, Sr. Director, External Innovation, Corporate Business Development, Eli Lilly and Company
  • Bill Podd, President, Landmark Angels and Landmark Family Office
  • Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital LLC
  • Alexander S. Preker, President & CEO, Health Investment & Financing Corporation
  • Barbara S. Schilberg, Managing Director and Chief Executive Officer, BioAdvance
  • Bavani Shankar, MBA, Senior Director, Business Development, Scientific Partnering & Alliances, AstraZeneca
  • Boris Shor, Life Sciences Investment Advisor, Primer Capital
  • Mark Simon, MBA, Partner, Torreya Partners
  • Bryan C. Spielman, Executive Vice President, Strategy and Corporate Development, Seven Bridges
  • Kathryn Stein, PhD, Principal, Kathryn Stein Consulting (Former Director, Division of Monoclonal Antibodies, FDA)
  • Gregory Q. Tiberend, President & CEO, Tiberend Strategic Advisors, Inc.
  • Stephen H. Tsang, MD, PhD, Associate Professor in Pathology & Cell Biology, László Bitó Associate Professor in Ophthalmology, Columbia University
  • Felicia Vonella, Executive Director, Investor Relations & Corporate Communications, Acorda Therapeutics
  • Geoffrey von Maltzahn, PhD, VentureLabs Partner, Flagship Ventures
  • Anton Xavier, MS, MBA, NY/NYC Biotech Scout, Targeted Therapeutics Discovery, Pfizer WRD
  • Peter Young, Executive-in-Residence, Pappas Ventures
  • Tingting Zhang-Kharas, PhD, Advisor – Oncology External Innovation, Eli Lilly and Company
  • Alex Zisson, Managing Director, H.I.G. Capital

Click here to view a list of our 2015 speakers